BioLineRx Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 24

Employees

  • Stock Symbol
  • BLRX

Stock Symbol

  • Investments
  • 5

BioLineRx General Information

Description

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Modi'in Technology Park
  • 2 HaMa'ayan Street
  • Modiin 7177871
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
TAE
Vertical(s)
Corporate Office
  • Modi'in Technology Park
  • 2 HaMa'ayan Street
  • Modiin 7177871
  • Israel
+972

BioLineRx Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioLineRx Stock Performance

As of 16-Nov-2026, BioLineRx’s current market cap is $9.3M with 2.99B shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.3M 2.99B 3.57M

BioLineRx Financials Summary

As of 30-Jun-2026, BioLineRx has a trailing 12-month revenue of $1.39M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 8,738 (1,287) 22,553 101,865
Revenue 1,392 1,180 28,940 4,800
EBITDA (9,459) (1,376) 2,098 (59,093)
Net Income (6,989) (1,175) (9,221) (60,614)
Total Assets 33,480 40,905 38,906 63,925
Total Debt 7,941 10,150 15,040 11,591
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioLineRx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioLineRx‘s full profile, request access.

Request a free trial

BioLineRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development an
Drug Discovery
Modiin, Israel
24 As of 2025

Cambridge, MA

Seal Beach, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioLineRx Competitors (32)

One of BioLineRx’s 32 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Formerly VC-backed Cambridge, MA
Dendreon Formerly VC-backed Seal Beach, CA
X4 Pharmaceuticals Formerly VC-backed Boston, MA
Rein Therapeutics Formerly VC-backed Austin, TX
Sagimet Biosciences Formerly VC-backed Foster City, CA
You’re viewing 5 of 32 competitors. Get the full list »

BioLineRx Patents

BioLineRx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025224720-A1 Methods of selecting treatment regimen against solid tumors Pending 24-Apr-2024
WO-2025032571-A1 Unit dosage forms and methods comprising bl8040 for intravenous administration Inactive 07-Aug-2023
JP-2026513170-A Methods for recruiting hematopoietic progenitor cells Pending 26-Mar-2023
AU-2024241828-A1 Methods of hematopoietic precursor cells mobilization Pending 26-Mar-2023
EP-4687960-A1 Methods of hematopoietic precursor cells mobilization Pending 26-Mar-2023 A61P35/02
To view BioLineRx’s complete patent history, request access »

BioLineRx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioLineRx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioLineRx‘s full profile, request access.

Request a free trial

BioLineRx Investments & Acquisitions (5)

BioLineRx’s most recent deal was a Joint Venture with GLIX1. The deal was made on 29-Sep-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GLIX1 29-Sep-2025 Joint Venture Drug Discovery
Biokine 03-Oct-2018 Corporate Drug Discovery
Agalimmune 23-Mar-2017 Merger/Acquisition Biotechnology
iPharma Labs 25-Aug-2016 Joint Venture Drug Discovery
Biokine Merger/Acquisition Drug Discovery
To view BioLineRx’s complete investments and acquisitions history, request access »

BioLineRx ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view BioLineRx’s complete esg history, request access »

BioLineRx Exits (1)

BioLineRx’s most recent exit was on 25-Aug-2016 from iPharma Labs. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
iPharma Labs 25-Aug-2016 Completed
  • 2 buyers
To view BioLineRx’s complete exits history, request access »

BioLineRx Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Biokine Rehovot, Israel 2000

BioLineRx FAQs

  • When was BioLineRx founded?

    BioLineRx was founded in 2003.

  • Where is BioLineRx headquartered?

    BioLineRx is headquartered in Modiin, Israel.

  • What is the size of BioLineRx?

    BioLineRx has 24 total employees.

  • What industry is BioLineRx in?

    BioLineRx’s primary industry is Drug Discovery.

  • Is BioLineRx a private or public company?

    BioLineRx is a Public company.

  • What is BioLineRx’s stock symbol?

    The ticker symbol for BioLineRx is BLRX.

  • What is the current market cap of BioLineRx?

    The current market capitalization of BioLineRx is $9.3M.

  • What is BioLineRx’s current revenue?

    The trailing twelve month revenue for BioLineRx is $1.39M.

  • Who are BioLineRx’s competitors?

    AnTolRx, Dendreon, X4 Pharmaceuticals, Rein Therapeutics, and Sagimet Biosciences are some of the 32 competitors of BioLineRx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process